摘要
目的:观察非酒精性脂肪性肝炎(nonalcoholic steatohepatitis,NASH)病人应用吡格列酮治疗后的疗效和不良反应。方法:将120例诊断为NASH的病人随机分为2组,对照组60例采用常规治疗,吡格列酮组60例除常规治疗外,加用口服吡格列酮30mg/次,1次/d,共6个月。比较两组病人治疗前后肝脏生化指标:丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)、总胆红素(Tbil),血脂指标:总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C),空腹血糖和空腹胰岛素水平,用CT测量肝/脾值及症状改善的临床疗效。结果:吡格列酮组治疗后肝脏ALT、AST、GGT与治疗前相比分别下降了26.6%、13.8%和39.3%;与同时期对照组相比分别下降了20.6%、16.0%和40.3%。CT肝/脾值比治疗前升高0.16,升高了26.2%;比对照组升高0.08,升高了11.6%。结论:吡格列酮对非酒精性脂肪肝炎有明显的治疗作用,无明显不良反应。
Objective：To observe the efficacy and adverse drug reactions（ADRs） of pioglitazone in treatment of patients with nonalcoholic steatohepatitis（NASH）.Methods：One hundred and twenty patients with NASH were randomly divided into control group and pioglitazone treatment group of 60 patients each.All the patients received conventional therapy and patients in pioglitazone group were additionally given pioglitazone 30 mg,qd,for 6 months.Alanine aminotransferase（ALT）,aspartate aminotransferase （AST）,gamma-glutamyl transpeptidase（GGT）,total bilirubin（Tbil）,total cholesterol（TC）,triglyceride（TG）,low density lipoprotein cholesterol（LDL-C）,high density lipoprotein cholesterol（HDL-C）,fasting blood glucose（FBG）,fasting insulin（FINS）,the ratio value of liver to spleen by CT determination and symptom improvement were measured before and after the treatment.Results：ALT,AST and GGT in pioglitazone treatment group were reduced by 26.6%,13.8% and 39.3% compared with those before the treatment.Compared with the patients in control group,ALT,AST and GGT of patients in pioglitazone treatment group were reduced by 20.6%,16.0% and 40.3%,respectively.The ratio value of liver to spleen by CT raised by 0.16（26.2%） compared with that before treatment and 0.08（11.6%） compared with control group.Conclusion：Pioglitazone therapy for 6 months is effective in the patients with NASH.No ADRs were observed.
出处
《药学服务与研究》
CAS
CSCD
2010年第3期221-223,共3页
Pharmaceutical Care and Research
作者简介
金惠（女），主治医师．E-mail：misshuijin@hotmail．com
通讯作者：周颖，E—mail：yingzhouwu@hotmail．com
